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BACKGROUND
Gastroenteritis accounts for approximately 1.7 million visits to the emergency depart-
ment (ED) by children in the United States every year. Data to determine whether the use 
of probiotics improves outcomes in these children are lacking.
METHODS
We conducted a randomized, double-blind trial involving 886 children 3 to 48 months of 
age with gastroenteritis who presented to six pediatric EDs in Canada. Participants re-
ceived a 5-day course of a combination probiotic product containing Lactobacillus rhamno-
sus R0011 and L. helveticus R0052, at a dose of 4.0×109 colony-forming units twice daily or 
placebo. The primary outcome was moderate-to-severe gastroenteritis, which was defined 
according to a post-enrollment modified Vesikari scale symptom score of 9 or higher 
(scores range from 0 to 20, with higher scores indicating more severe disease). Secondary 
outcomes included the duration of diarrhea and vomiting, the percentage of children who 
had unscheduled physician visits, and the presence or absence of adverse events.
RESULTS
Moderate-to-severe gastroenteritis within 14 days after enrollment occurred in 108 of 414 
participants (26.1%) who were assigned to probiotics and 102 of 413 participants (24.7%) 
who were assigned to placebo (odds ratio, 1.06; 95% confidence interval [CI], 0.77 to 
1.46; P = 0.72). After adjustment for trial site, age, detection of rotavirus in stool, and 
frequency of diarrhea and vomiting before enrollment, trial-group assignment did not 
predict moderate-to-severe gastroenteritis (odds ratio, 1.06; 95% CI, 0.76 to 1.49; P = 0.74). 
There were no significant differences between the probiotic group and the placebo group 
in the median duration of diarrhea (52.5 hours [interquartile range, 18.3 to 95.8] and 
55.5 hours [interquartile range, 20.2 to 102.3], respectively; P = 0.31) or vomiting (17.7 
hours [interquartile range, 0 to 58.6] and 18.7 hours [interquartile range, 0 to 51.6], 
P = 0.18), the percentages of participants with unscheduled visits to a health care pro-
vider (30.2% and 26.6%; odds ratio, 1.19; 95% CI, 0.87 to 1.62; P = 0.27), and the percent-
age of participants who reported an adverse event (34.8% and 38.7%; odds ratio, 0.83; 
95% CI, 0.62 to 1.11; P = 0.21).
CONCLUSIONS
In children who presented to the emergency department with gastroenteritis, twice-daily 
administration of a combined L. rhamnosus–L. helveticus probiotic did not prevent the de-
velopment of moderate-to-severe gastroenteritis within 14 days after enrollment. (Funded 
by the Canadian Institutes of Health Research and others; PROGUT ClinicalTrials.gov 
number, NCT01853124.)
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A cute gastroenteritis accounts for approximately 1.7 million emergency de-partment (ED) visits among children in the 
United States every year.1 Although health care 
providers traditionally have had little to offer to 
modify the disease course,2 probiotics are an 
expanding multibillion-dollar industry3 with po-
tential clinical benefits.4 Consumers increasingly 
take probiotics to treat intestinal infections,5,6 
and 5 of 12 leading guidelines endorse the use 
of probiotics.7 Most studies of probiotics with 
results that have been published have had meth-
odologic limitations and small sample sizes, have 
included limited investigations of causative patho-
gens, and have not reported adverse events.8 
Numerous individual symptoms have been used 
as outcomes, but evaluations that incorporate both 
the duration and frequency of both diarrhea and 
vomiting are lacking.9 Given the distressing symp-
toms of gastroenteritis10,11 and the lack of benefit 
of probiotics shown in one North American 
study that enrolled children who received care in 
the ED,12 the role of probiotics in outpatient 
management of acute gastroenteritis in children 
warrants clarification.
We conducted the Pediatric Emergency Re-
search Canada (PERC) Probiotic Regimen for 
Outpatient Gastroenteritis Utility of Treatment 
(PROGUT) trial to evaluate the effectiveness of 
probiotics in children 3 to 48 months of age who 
present to the ED with acute gastroenteritis. We 
hypothesized that the percentage of children 
with moderate-to-severe gastroenteritis (defined 
according to a validated severity score13,14) within 
14 days after enrollment would be significantly 
lower among those who received probiotics than 
among those who received placebo.
Me thods
Trial Design and Oversight
In this multicenter, randomized, double-blind, 
placebo-controlled trial, participants with diar-
rhea were enrolled in six Canadian tertiary-care, 
university-affiliated, pediatric EDs. We sought to 
determine whether the administration of a two-
strain, commercially available probiotic product 
(Lacidofil Strong, Lallemand Health Solutions) 
would be superior to placebo at reducing the 
severity of symptoms of acute gastroenteritis. 
Parents or guardians provided written informed 
consent for their children to participate. Partici-
pants received a 5-day course of combined Lacto-
bacillus rhamnosus R0011 and L. helveticus R0052 
at a dose of 4.0×109 colony-forming units (CFU) 
twice daily or placebo.
Probiotic and placebo sachets were provided 
free of charge by Lallemand Health Solutions, 
which tested quantitative bacterial cultures ob-
tained from unused sachets. None of the funders 
had any input into the design or conduct of the 
trial; the collection, management, analysis, or 
interpretation of the data; the preparation, review, 
or approval of the manuscript; or the decision to 
submit the manuscript for publication. Research 
ethics boards at the participating sites approved 
the trial (see the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org). 
The full protocol and statistical analysis plan are 
available at NEJM.org.15 All the authors vouch for 
the completeness and accuracy of the data and 
analyses presented and for the fidelity of the 
trial to the protocol.
Trial Participants
Children 3 to 48 months of age were eligible for 
participation if they presented to the ED, had 
three or more episodes of watery stools in a 24-
hour period,16 had vomiting or diarrhea for less 
than 72 hours, and had received a clinical diag-
nosis (i.e., by the responsible physician) of an 
acute intestinal infection. Children were exclud-
ed if they or a person living in their household 
had an indwelling vascular-access catheter or if 
they had structural heart disease,17 were immuno-
compromised,18 or were receiving immunosup-
pressive therapy. Additional exclusion criteria were 
hematochezia, bilious vomiting, a chronic gastro-
intestinal disorder (e.g., inflammatory bowel dis-
ease or the short gut syndrome), pancreatic dys-
function or insufficiency,19 the use of probiotics 
during the preceding 14 days, an allergy to soy, 
and an inability to complete follow-up. Children 
who had undergone oral or gastrointestinal sur-
gery within the preceding 7 days or had previ-
ously participated in the trial were also excluded. 
Concomitant use of antibiotics was permitted.
Randomization and Blinding
Random-number–generating software, accessed 
through a Web-based randomization system (www 
.randomize.net), which used random block sizes 
of 4 and 6 and a 1:1 trial-group assignment ratio 
stratified according to site, was used to sequen-
tially assign children to probiotics or placebo. 
The assignment sequence was restricted to the 
A Quick Take 
is available at 
NEJM.org
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research pharmacy at the coordinating center 
and www.randomize.net until the databases were 
locked. Participants and their parents or guard-
ians, trial and clinical staff, and specimen and 
data analysts were unaware of the trial-group 
assignments.
Procedures
The probiotic preparation is a lyophilized powder 
containing 4.0×109 CFU of two bacterial strains 
— L. rhamnosus R0011 and L. helveticus R0052 — 
in a 95:5 ratio. Sachets containing placebo and 
probiotics were identical in appearance, smell, 
and weight. The contents of one sachet contain-
ing the probiotics or placebo, which had been 
maintained at a temperature between 0° and 
25°C, were sprinkled into 30 ml of the child’s 
preferred liquid twice daily.20 Five extra sachets 
were included in each kit to enable repeat dosing 
if vomiting occurred within 15 minutes after 
administration. Quantitative bacterial culture of 
the investigational product was performed when 
the use of each batch of the probiotic preparation 
was completed (see the Supplementary Appendix).
Research assistants collected demographic data 
and data on clinical characteristics and com-
pleted trial interventions in the ED. To maxi-
mize accuracy and minimize recall bias, parents 
or guardians completed electronic or telephone 
follow-up surveys every 24 hours until both vom-
iting and diarrhea had ceased in the participant 
for 24 hours. Survey questions targeted clinical 
symptoms, health care utilization, and adverse 
events during the preceding 24-hour period. On 
day 5, parents or guardians reported the adher-
ence to the trial regimen (i.e., the number of 
sachets received of the number prescribed) and 
were asked to return all unused sachets for enu-
meration. If the two approaches to documenta-
tion of adherence differed, we determined a priori 
that the sachet count would be used.
Rectal swabs, stool specimens, or both were 
obtained during the enrollment visit.21 Bacterial 
culture was performed locally. A multiplex nu-
cleic acid panel that detects 15 enteric viruses, 
bacteria, and parasites (Luminex xTAG Gastro-
intestinal Pathogen Panel) (see the Supplemen-
tary Appendix) was performed at the Provincial 
Laboratory for Public Health–Alberta Public Lab-
oratories, in Edmonton, Alberta, Canada.22
Outcomes
The primary outcome was the occurrence of 
moderate-to-severe gastroenteritis, which was 
defined according to a total modified Vesikari 
scale symptom score of 9 or higher (scores range 
from 0 to 20, with higher scores indicating more 
severe disease) (Table 1, and the Supplementary 
Appendix).13,24 The score was based on symptoms 
during the follow-up period and was calculated 
at the day 14 follow-up. The modified Vesikari 
scale quantifies severity over a broad range of 
symptoms and interventions,25 has been designed 
for outpatients, and was validated at most of the 
participating hospitals.13,14,26 The 14-day timeline 
was used to capture relationships between the use 
Scale component Score on the Vesikari Scale
0 Points 1 Point 2 Points 3 Points
Duration of diarrhea (hr) 0 1–96 97–120 ≥121
Maximum no. of watery stools per 24 hr 0 1–3 4–5 ≥6
Duration of vomiting (hr) 0 1–24 25–48 ≥49
Maximum no. of vomiting episodes per 24 hr 0 1 2–4 ≥5
Maximum recorded rectal temperature (°C)† <37.0 37.1–38.4 38.5–38.9 ≥39.0
Unscheduled health care visit None NA Primary care Emergency 
 department
Treatment None Rehydration with 
 intravenous fluids
Hospitalization NA
*  In the modified Vesikari scale score, one variable (percent dehydration) in the original score was replaced with the vari‑
able of unscheduled health care visits to better measure the effect of acute gastroenteritis in outpatients, given that the 
ability to perform frequent in‑person assessments in an outpatient cohort of children can be challenging. Scores range 
from 0 to 20, with higher scores indicating more severe disease. Children with a score of 9 or more were considered to 
have moderate‑to‑severe gastroenteritis.13,14 NA denotes not applicable.
†  Temperatures were adjusted for the location of measurement: 1.1°C was added to axillary temperatures and 0.6°C was 
added to oral temperatures.23
Table 1. Modified Vesikari Scale.*
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF WESTERN ONTARIO on March 27, 2019. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 379;21 nejm.org November 22, 20182018
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
of probiotics and differences from placebo in 
the percentages of children who had prolonged 
diarrhea.27 Baseline symptoms that occurred be-
fore the visit to the ED were not included in the 
outcome measure.
Secondary outcomes specified a priori includ-
ed the duration of diarrhea and the duration of 
vomiting after enrollment; unscheduled visits to 
a health care provider for vomiting, diarrhea, 
dehydration, fever, or because the participant de-
clined to drink fluids within 14 days after en-
rollment; and adverse events, which were coded 
with the use of definitions from the Medical Dic-
tionary for Regulatory Activities, version 19.0. Addi-
tional outcomes specified a priori included the 
number of repeat visits to the ED, intravenous 
rehydration, hospitalization, the number of days 
of work missed by parents or guardians, and the 
number of days of day care missed by participants.
Statistical Analysis
We assumed that moderate-to-severe gastroen-
teritis would occur in 25% of the children who 
received placebo.13,14 At a significance level of 5%, 
we calculated that a sample of 670 participants 
would provide the trial with 90% power to detect 
an absolute between-group difference of 10 per-
centage points in the outcome. We intended to 
recruit 886 participants to allow for a rate of loss 
to follow-up of 10%, a dropout rate of 5%, and 
a crossover rate of 2.5%, with adjustment for 
O’Brien–Fleming monitoring boundaries. Conser-
vative boundaries, implemented with the use of 
the Lan–DeMets alpha-spending function, guided 
the early stopping boundary for safety or effi-
cacy. All statistical tests of hypotheses were two-
sided. The data and safety monitoring commit-
tee (see the Supplementary Appendix) met after 
200 and 500 participants were recruited.
All analyses were specified a priori.15 We in-
cluded data from all participants who underwent 
randomization, according to the intention-to-treat 
principle. Multiple imputation was used to ac-
count for missing data. The model assumed that 
data were missing at random and included key 
baseline characteristics, trial group, and all effi-
cacy outcomes. The overall significance level for 
statistical tests of secondary and tertiary out-
comes was set at 0.05. The Holm method was 
used to adjust for multiple comparisons.28 Analy-
ses were performed with SPSS software, version 
24.0.0.1 (IBM), and Stata software, version 15.0 
(StataCorp).
Baseline variables were summarized with the 
use of standard descriptive statistics. Logistic 
regression, stratified according to trial site, was 
used to estimate odds ratios and 95% confi-
dence intervals for the risk of moderate-to-severe 
gastroenteritis associated with probiotics as 
compared with placebo. Secondary analysis of 
the primary outcome included adjustment for 
other covariates identified a priori as being 
prognostic of the outcomes.29 These covariates 
were age, frequency of vomiting and diarrhea in 
the 24-hour period before enrollment, trial site, 
and rotavirus infection. We compared the per-
centage of participants with modified Vesikari 
scores of 9 or higher after randomization, ac-
counting for the interaction with the interven-
tion, in subgroups according to age (<1 year vs. 
≥1 year), whether the child had been exclusively 
breast-fed, use of oral antibiotics in the 14 days 
before enrollment, and adherence to the trial 
regimen (receipt of >70% of doses prescribed). 
The effect of rotavirus infection was evaluated in 
a logistic-regression model through the addition 
of an interaction term combining detection of 
rotavirus infection and trial group. The modi-
fied Vesikari score was also analyzed as a con-
tinuous variable with the use of a linear-regres-
sion model with adjustment for site.
Secondary outcomes were adjusted for trial 
site with the use of the appropriate regression 
models. The durations of diarrhea and vomiting 
were measured in hours and compared between 
groups with the use of a linear-regression mod-
el. The outcome of duration of vomiting includ-
ed only participants with three or more episodes 
of vomiting in the 24-hour period before enroll-
ment. Incidence rate ratios were analyzed to 
compare the number of episodes of diarrhea and 
vomiting after enrollment with the use of a 
negative binomial model that included terms for 
trial group, trial site, and the number of epi-
sodes of diarrhea, vomiting, or both, in the 24 
hours before enrollment. The percentages of 
children who had unscheduled health care visits 
and any adverse event were compared with the 
use of logistic-regression models. The subgroups 
of children who attended day care and gainfully 
employed parents or guardians were evaluated 
for absenteeism with the use of the van Elteren 
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test.30 Exploratory analyses are described in the 
Supplementary Appendix.
R esult s
Participants
From November 5, 2013, through April 7, 2017, 
a total of 886 participants were enrolled and 
underwent randomization (Fig. 1). A total of 414 
of the 444 participants who were assigned to 
receive probiotics (93.2%) and 413 of the 442 
participants who were assigned to receive pla-
cebo (93.4%) completed follow-up. Among the 
participants for whom data on the number of 
doses administered could be evaluated, the per-
centage of participants who received more than 
70% of the doses prescribed did not differ signifi-
cantly between the groups (295 of 383 partici-
pants [77.0%] in the probiotic group and 303 of 
378 participants [80.2%] in the placebo group). 
Rotavirus A infection was identified more often 
in participants in the probiotic group than in the 
placebo group; otherwise, the trial groups were 
well matched with respect to baseline character-
Figure 1. Enrollment, Randomization, and Outcomes.
Some participants met more than one criterion for exclusion.
886 Underwent randomization
2663 Patients were assessed for eligibility
1777 Were excluded
1049 Declined to participate
682 Met exclusion criteria
206 Could not complete follow-up
147 Had hematochezia, inflammatory
bowel disease, or short gut syndrome
132 Used supplemental probiotics in
preceding 14 days
60 Had structural heart disease
32 Had immunodeficiency or received 
immunosuppressive therapy
26 Had family member with vascular-
access catheter or immunodeficiency
or who received immunosuppressive
therapy
26 Had bilious vomiting
25 Had allergy to soy
13 Were previously enrolled
9 Had vascular-access catheter
6 Underwent oral or gastrointestinal
surgery in preceding wk
3 Had pancreatic dysfunction
or insufficiency
46 Had other reasons
444 Were assigned to receive probiotics 442 Were assigned to receive placebo
30 Were excluded
18 Were lost to follow-up
12 Withdrew
29 Were excluded
10 Were lost to follow-up
19 Withdrew
414 Completed follow-up and were included
in the modified intention-to-treat analysis
413 Completed follow-up and were included
in the modified intention-to-treat analysis
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istics (Table 2), discharge diagnoses (Table S1 in 
the Supplementary Appendix), and coadminis-
tered medications (Table S2 in the Supplemen-
tary Appendix).
Primary Outcome
The percentage of participants who had a modi-
fied Vesikari score of 9 or higher after enroll-
ment was similar in the two groups (26.1% in 
the probiotic group [108 of 414 participants] and 
24.7% in the placebo group [102 of 413 partici-
pants]; difference, 1.4 percentage points; 95% 
confidence interval [CI], −4.5 to 7.3; P = 0.65). 
Regression analysis with adjustment for trial site 
showed no benefit of probiotic use (odds ratio, 
1.06; 95% CI, 0.77 to 1.46; P = 0.72) (Table 3). In 
a multivariable analysis, trial-group assignment 
did not predict moderate-to-severe gastroenteri-
Characteristic
Probiotic Group 
(N = 440)
Placebo Group 
(N = 437)
Median age (IQR) — mo 16.0 (10.0–24.8) 15.0 (9.5–24.0)
Male sex — no. (%) 243 (55.2) 252 (57.7)
Median weight (IQR) — kg 10.6 (9.0–13.0) 10.7 (8.8–12.6)
Exclusively breast‑fed — no. (%) 23 (5.2) 32 (7.3)
Received antibiotics in previous 14 days — no. (%) 56 (12.7) 63 (14.4)
Received rotavirus vaccine — no. (%) 214 (48.6) 213 (48.7)
Median duration of illness (IQR) — hr† 42.5 (26.7–58.1) 43.8 (27.7–58.8)
Median modified Vesikari score (IQR)‡ 10 (9–12) 10 (8–12)
Vomiting — no. (%) 345 (78.4) 327 (74.8)
Median no. of vomiting episodes in preceding 24 hr (IQR)§ 5 (3–8) 5 (2–8)
Median no. of diarrhea episodes in preceding 24 hr (IQR) 6 (4–8) 6 (4–9)
Febrile — no. (%)¶ 198 (45.0) 196 (44.9)
Median clinical dehydration scale score (IQR)‖ 1 (0–2) 0 (0–2)
Received ondansetron at index visit — no./total no. (%) 100/440 (22.7) 91/437 (20.8)
Received intravenous rehydration at index visit — no./total no. (%) 40/440 (9.1) 33/437 (7.6)
Admitted to hospital at index visit — no./total no. (%) 11/439 (2.5) 11/437 (2.5)
Stool testing results — no./total no. (%)**
Norovirus GI or GII 102/432 (23.6) 124/428 (29.0)
Rotavirus A 124/432 (28.7) 85/428 (19.9)
Clostridium difficile toxin A or B 51/432 (11.8) 61/428 (14.3)
Adenovirus 40 or 41 50/432 (11.6) 45/428 (10.5)
Salmonella 11/432 (2.6) 9/428 (2.1)
*  No significant differences were observed between the groups in any of the baseline characteristics, with the exception 
of positivity for rotavirus infection (P = 0.003). However, after adjustment for pairwise comparisons of 12 pathogens, 
none of the differences remained significant. For variables for which data were missing, summary data are based on 
the adjusted number. Four participants in the probiotic group and five in the placebo group withdrew from the trial 
before they provided baseline demographic information. Additional data are provided in Table S9 in the Supplemen‑
tary Appendix. IQR denotes interquartile range.
†  This variable was defined according to the duration of vomiting or the duration of diarrhea before enrollment, which‑
ever was greater.
‡  Scores on the modified Vesikari scale range from 0 to 20, with higher scores indicating greater disease severity.13,14
§  The denominator for this variable was the number of children who had vomiting.
¶  Febrile was defined as a documented adjusted rectal temperature of at least 38.0°C.
‖  Scores on the clinical dehydration scale range from 0 to 8, with higher scores indicating more severe dehydration.31,32
**  A participant may have tested positive for more than one pathogen; all detected pathogens are reported. Results are 
reported for the children from whom submitted specimens were obtained for analysis. Only pathogens identified in 
more than 10 participants per trial group are listed.
Table 2. Baseline Characteristics of the Enrolled Participants.*
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tis (odds ratio, 1.06, 95% CI, 0.76 to 1.49; P = 0.74) 
(Table S3 in the Supplementary Appendix).
No significant difference was observed in the 
percentage of participants with a modified Vesi-
kari score of 9 or higher in any of the subgroups 
defined a priori (Table S4 in the Supplementary 
Appendix). There was no interaction between 
trial-group assignment and the age of the partici-
pants (P = 0.72), antibiotic use in the preceding 
14 days (P = 0.80), exclusive breast-feeding (P = 0.57), 
and receipt of more than 70% of the doses pre-
scribed (P = 0.59). The interaction between detec-
tion of rotavirus in stool and trial group was not 
significant (P = 0.99) (Table S5 in the Supplemen-
tary Appendix). When the modified Vesikari score 
was analyzed as a continuous variable, there was 
Outcome and Subgroup Probiotic Group Placebo Group Odds Ratio (95% CI) P Value
Primary efficacy outcome: modified Vesikari score of ≥9†‡
All participants — no./total no. (%) 108/414 (26.1) 102/413 (24.7) 1.06 (0.77–1.46) 0.72
Age <1 yr — no./total no. (%)  45/134 (33.6) 48/150 (32.0) 1.01 (0.60–1.71) 0.97
Exclusively breast‑fed — no./total no. (%)    7/22 (31.8) 10/31 (32.3) 0.82 (0.18–3.61)  0.79§
Receipt of antibiotics within 14 days before index visit  
— no./total no. (%)
  12/51 (23.5) 17/59 (28.8) 0.86 (0.35–2.11)   0.74¶
Adherence to trial regimen, defined as having received >70% 
of doses prescribed — no./total no. (%)
 72/295 (24.4) 66/303 (21.8) 1.16 (0.79–1.71) 0.45
Secondary efficacy outcomes
Median duration of diarrhea in 827 participants (IQR) — hr    52.5 (18.3–95.8)    55.5 (20.2–102.3) 0.31
Median duration of vomiting in 409 participants (IQR) — hr‖ 17.7 (0–58.6) 18.7 (0–51.6) 0.18
Visit to health care provider — no./total no. (%)† 125/414 (30.2) 110/413 (26.6) 1.19 (0.87–1.62) 0.27
Any adverse event — no./total no. (%)** 136/414 (32.9) 152/413 (36.8) 0.83 (0.62–1.11) 0.21
Tertiary efficacy outcomes
Median no. of days of day care missed in 331 participants 
(IQR)††
1.0 (0–2.0) 1.0 (0–2.0) 0.55
Median no. of hours of work missed by parent or guardian  
of 653 participants (IQR)‡‡
 0 (0–8.0)  0 (0–8.8) 0.18
Repeat visit to ED
No. of participants/total no. (%)† 83/414 (20.0) 76/413 (18.4) 1.11 (0.77–1.60) 0.56
With administration of intravenous fluid — no./total no. (%)† 36/414 (8.7) 26/413 (6.3) 1.57 (0.75–3.28)§§ 0.23
With hospitalization — no./total no. (%)† 33/414 (8.0) 22/413 (5.3) 1.65 (0.66–4.12)¶¶ 0.28
*  CI denotes confidence interval, and ED emergency department.
†  This outcome was analyzed with the use of logistic regression, and the model was adjusted for the enrollment site.
‡  Scores on the modified Vesikari scale range from 0 to 20, with higher scores indicating greater disease severity.
§  The regression analysis excluded participants from three sites, since all exclusively breast‑fed children at these sites were either in one 
group (either probiotic or placebo) or had the outcome of interest.
¶  The regression analysis excluded five participants from one site, since they all had the outcome of interest.
‖  Data include only participants with three or more episodes of vomiting in the 24 hours before enrollment.
**  This outcome was analyzed with the use of logistic regression, and the model was adjusted for enrollment site; however, no imputation 
was performed for participants with missing data on adverse events.
††  These data, which include only children who attended day care, were analyzed with the use of the van Elteren test stratified according to 
enrollment site. No imputation was performed for participants with missing data on day‑care absenteeism. Attendance in day care was 
defined as being cared for at least 2 half days (2.5 hours per day) per week by a relative or nonrelative, in a child care center, at home,  
or in someone else’s home where there were, on average, a minimum of three children, including the index child.
‡‡  These data, which include only parents or guardians who worked, were analyzed with the use of the van Elteren test stratified according to 
 enrollment site. No imputation was performed for participants with missing data on work absenteeism.
§§  The regression analysis excluded participants from a single site, since none of the 11 children who had a repeat visit to the ED at this site 
received intravenous fluids.
¶¶  The regression analysis excluded participants from three sites, since none of the 23 children who had a repeat visit to the ED at these sites 
were admitted to the hospital.
Table 3. Trial Outcomes and Subgroups.*
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no significant difference between the trial groups 
(mean [±SD], 6.0±4.6 in the probiotic group and 
5.8±4.4 in the placebo group; P = 0.44). There 
was no evidence of benefit of probiotics accord-
ing to the pathogen identified (Table S6 in the 
Supplementary Appendix).
Secondary Outcomes
No significant difference between the groups 
was found with regard to the median duration 
of diarrhea (52.5 hours [interquartile range, 18.3 
to 95.8] in the probiotic group and 55.5 hours 
[interquartile range, 20.2 to 102.3] in the placebo 
group) and vomiting (17.7 hours [interquartile 
range, 0 to 58.6] in the probiotic group and 18.7 
hours [interquartile range, 0 to 51.6] in the pla-
cebo group) (P = 0.31 and P = 0.18, respectively) 
(Table 3). Although the total number of episodes 
of diarrhea did not differ significantly between 
the groups (incidence rate ratio, 0.98; 95% CI, 
0.85 to 1.13; P = 0.78) (Fig. 2A), the number of 
episodes of vomiting was significantly higher in 
the probiotic group than in the placebo group 
(incidence rate ratio, 1.36; 95% CI, 1.13 to 1.63; 
P<0.001) (Fig. 2B). The percentage of children 
who had unscheduled health care visits did not 
differ significantly between the groups (30.2% 
[125 of 414 children] in the probiotic group and 
26.6% [110 of 413 children] in the placebo group; 
odds ratio, 1.19; 95% CI, 0.87 to 1.62; P = 0.27).
An adverse event was reported in 34.8% (144 
of 414) of the participants who received probiot-
ics and 38.7% (160 of 413) of the participants 
who received placebo (odds ratio, 0.83; 95% CI, 
0.62 to 1.11; P = 0.21) (Table S7 in the Supple-
mentary Appendix). Two children in the placebo 
group had serious adverse events. One had a fe-
brile seizure 6 hours after receiving the first dose 
of the trial agent and 1 received a diagnosis of 
Kawasaki disease 3 days after enrollment.
Exploratory Analyses
There was no evidence of an interaction between 
trial group and the duration of symptoms at 
enrollment (P = 0.54), detection of bacteria in the 
stool (P = 0.86), or modified Vesikari score be-
fore enrollment (P = 0.86). However, the modi-
fied Vesikari scale score before enrollment was 
associated with the primary outcome in the re-
gression model (odds ratio, 1.14; 95% CI, 1.06 to 
1.23; P = 0.001). None of the results were signifi-
cantly altered when the outcome of severe dis-
ease (i.e., a modified Vesikari score of ≥11) was 
considered (Table S8 in the Supplementary Ap-
pendix).
Discussion
In this trial involving children who had had 
symptoms of gastroenteritis for up to 72 hours 
and presented to the ED, a 5-day course of twice-
daily administration of a combined probiotic 
formulation (4.0×109 CFU of a combination 
L. rhamnosus and L. helveticus) did not prevent the 
development of moderate-to-severe gastroenteri-
tis. Among these children with predominantly vi-
ral infection, probiotics did not result in benefits 
Figure 2. Episodes of Diarrhea and Vomiting, According to Trial Group.
Shown are the mean numbers of episodes of diarrhea (Panel A) and vomit‑
ing (Panel B) per 24‑hour period after enrollment. Data on all participants 
are included, irrespective of the number of vomiting episodes that occurred 
before enrollment. I bars denote the standard error.
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related to secondary outcomes. Adjustment for 
potential risk factors did not alter the findings.
Although the quality of evidence has been 
deemed by Szajewska et al. to be “low” or “very 
low,”33 many experts consider acute infectious 
diarrhea to be the main indication for probiotic 
use.7 Guideline recommendations vary from “not 
recommended” by the Centers for Disease Con-
trol and Prevention and the National Institute 
for Health and Care Excellence34,35 to “strongly 
recommended” by the European Society for Pedi-
atric Gastroenterology, Hepatology, and Nutri-
tion.36 These recommendations are largely based 
on meta-analyses such as a 2010 Cochrane re-
view.37 Although the authors of this review iden-
tified 63 eligible studies, they deemed only 10 to 
be methodologically adequate. The main finding 
of the review was a reduction of 25 hours in the 
mean duration of diarrhea; however, there was 
significant heterogeneity (assessed with I2 values) 
that may have been due to differences in the 
trial populations. Seven of the included studies 
recruited outpatients, and none of the studies 
were performed in the United States or Canada. 
A previous North American, ED-based study that 
included 155 participants12 showed no signifi-
cant effect of another probiotic, L. rhamnosus GG, 
on any outcomes identified a priori.
The aforementioned Cochrane review showed 
a reduction of 29 hours in the duration of diar-
rhea among children with rotavirus infection.37 
In vitro and in vivo studies have revealed poten-
tial mechanisms of probiotic action against rota-
virus, including the production of antimicrobial 
substances, stimulation of antimicrobial peptides 
and local adaptive and innate immune respons-
es, and epithelial-cell mucin production.38 None-
theless, no beneficial effect of probiotics was 
observed in this subgroup in our trial.
Rather than emphasizing a single symptom,39 
we focused on the overall severity of a constella-
tion of symptoms associated with gastroenteritis, 
quantified with the use of the modified Vesikari 
scale score. This approach quantitatively balances 
the frequency against the duration of symptoms. 
Analysis of a composite severity measure and of 
individual symptoms and subgroups of partici-
pants who were adherent to the trial regimens, 
as well as other measures of effectiveness, showed 
no significant difference between the groups 
and consistently showed no benefit of the probi-
otic strains at the dose evaluated. Although we 
studied only a single titer, the amount selected 
was higher than that recommended by the manu-
facturer,40 and at the end of their shelf life, we 
confirmed that organism counts were in the tar-
get range (6.13×109 to 9.36×109 CFU per sachet); 
thus, underdosing was unlikely.
Differences in preparations of probiotics may 
account for differences in outcomes across studies. 
The strain ratio (95:5) and dose of the L. rhamno-
sus R0011 and L. helveticus R0052 used in our trial 
were based on data from previous studies that 
showed them to be the most economical means 
to achieve the maximum benefit. This combina-
tion was selected for this trial because the strains 
have been evaluated for safety41 and efficacy in 
animal models and in small clinical trials involv-
ing humans.42 In vitro, the strains have been 
shown to have benefits, including exopolysac-
charide production,43 adhesion and barrier func-
tion,44 pathogen inhibition,45 and immune re-
sponse modulation.46 In humans, the R0011 
strain survives gut transit,47 and it is approved by 
Health Canada to treat antibiotic-associated and 
acute infectious diarrhea. The R0011 strain con-
tains the L. rhamnosus GG genes encoding the 
soluble proteins p75 and p40, which promote 
signaling pathways that are specific to intestinal 
epithelial homeostasis.48 However, R0011 differs 
from GG in pilus gene clusters; thus, the two 
strains produce different functional pili.48
Our trial has several limitations. Although we 
performed daily follow-up to maximize accuracy 
in the ascertainment of outcomes, we cannot rule 
out recall bias. The use of composite outcome 
measures has been questioned, since they may 
be subject to inconsistent and selective reporting 
and post hoc modifications.49 To overcome these 
concerns, we selected the modified Vesikari 
scale, which has face, content, and construct 
validity and is externally validated.13,14 Analysis 
of all individual score elements supported the 
conclusions based on our primary outcome. 
Since we used a specific probiotic product and 
dose, the conclusions cannot be generalized to 
all products on the market. However, large, well-
conducted clinical trials50-52 have aroused similar 
concerns regarding the effectiveness of probiot-
ics for other conditions. Nonetheless, there may 
be specific indications and populations that will 
benefit from alternative probiotic agents.53 Since 
our trial was conducted in Canadian EDs, the 
findings should be interpreted in that context 
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with consideration given to local host micro-
biomes and infectious pathogens. Our findings 
cannot be extrapolated to longer-term use of 
probiotics or other outcomes such as stunting in 
regions where bacterial and protozoal infections 
are more common.54
In conclusion, we found that a twice-daily, 
5-day course of 4.0×109 CFU of a combined 
L. rhamnosus and L. helveticus probiotic did not 
prevent the development of moderate-to-severe 
gastroenteritis within 14 days after enrollment 
in infants and young children who had had 
symptoms of gastroenteritis for up to 72 hours 
and had been brought for care in the emergency 
department.
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